CION Ameerpet
Most people carry the Epstein-Barr virus and never develop lymphoma. This guide explains, calmly and clearly, how EBV and glandular fever relate to lymphoma risk, which subtypes are linked, and how CION's haematology team tests for and treats EBV-associated lymphoma.
If you have searched for ebv lymphoma after a glandular fever diagnosis, a worrying blog post, or an "EBV-positive" line on a report, take a breath first. The Epstein-Barr virus (EBV) is one of the most common viruses on earth — by adulthood, the large majority of people carry it, almost always after a harmless childhood infection or an episode of glandular fever (infectious mononucleosis) in the teenage years. Carrying EBV is normal, and the overwhelming majority of people who carry it never develop lymphoma.
So where does the epstein barr virus lymphoma link come from? In a small minority of people — and usually alongside other influences such as reduced immunity — EBV can play a part in how certain lymphomas develop. The virus is one contributing risk factor, not a switch that turns cancer on. This page explains that relationship honestly: the real (and reassuringly small) risk, which lymphoma subtypes are EBV-associated, how doctors actually test for it, and how it is treated.
For the wider picture of what lymphoma is, see our Lymphoma hub. If you have a confirmed diagnosis and want to understand the pathway, our Lymphoma Treatment in Hyderabad page covers diagnosis, staging and treatment in depth.
The Epstein-Barr virus is astonishingly common — the World Health Organization notes that more than 90% of adults worldwide have been infected with EBV at some point, usually without ever knowing it. Yet lymphoma remains uncommon. This gap is the single most important thing to hold on to: being an EBV carrier is the norm, while EBV-associated lymphoma is the rare exception. (Source: World Health Organization / published EBV seroprevalence data, consistent with NCCN and ESMO background.)
Many people arrive here because of a past bout of glandular fever. Glandular fever is simply the illness caused by a first, symptomatic EBV infection — typically in teenagers and young adults, with fever, sore throat, swollen glands and weeks of fatigue. The connection people worry about is real but easily misread.
Large population studies have found that people who had symptomatic glandular fever carry a modestly higher relative risk of Hodgkin lymphoma, especially in the years soon after the infection. The word that matters here is relative. Because Hodgkin lymphoma is itself uncommon, the absolute risk to any individual who has had glandular fever stays very low — the vast majority never develop it. A history of glandular fever lymphoma concern is not a reason for routine cancer screening, and it does not mean cancer is coming.
What it does mean is straightforward: if you ever develop a lump, swelling or symptom that is new, persistent and unexplained, get it checked — the same sensible advice that applies to everyone. Prompt assessment, not anxiety, is the useful response.
EBV is not tied to a single lymphoma. Instead, it is detectable in the tumour cells of a proportion of several subtypes. Being EBV-positive is confirmed on the biopsy — it is one piece of the diagnostic picture.
EBV is found in the tumour (Reed-Sternberg) cells of a share of classic Hodgkin lymphoma cases. This is the subtype most associated with a prior glandular fever. Hodgkin lymphoma is also among the most treatable lymphomas.
The endemic form of Burkitt lymphoma — seen mainly in equatorial regions and often in children — is strongly EBV-associated. It is a fast-growing but highly treatment-responsive lymphoma.
A subset of diffuse large B-cell lymphoma is EBV-positive, recognised as its own category. EBV status here is one factor among stage, subtype and cell-of-origin markers that the tumour board weighs together.
This uncommon lymphoma, often affecting the nose and sinuses, is characteristically EBV-driven. Confirming EBV in the tissue is part of making the diagnosis.
When the immune system is weakened, EBV is less well controlled. This underlies post-transplant lymphoproliferative disorder (PTLD) and contributes to HIV-associated lymphomas.
EBV sits within a wider landscape of lymphoma influences. Explore related pages on family risk, autoimmune disease and other infection-linked lymphomas to see the full context.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Whether you are anxious after glandular fever, have an EBV-positive result, or need a second opinion before treatment, CION's haematology and lymphoma team is here to explain it clearly.
An important clarification: whether a lymphoma is "EBV-positive" is decided on the tumour tissue, not on a routine blood antibody test. Blood tests can tell you that you have been exposed to EBV — which, again, is true for most adults — but they do not tell you whether the virus is inside a lymphoma. CION arranges the specialist tissue testing and reviews it as part of the diagnostic work-up.
The definitive test is EBER in-situ hybridisation, performed by a pathologist on the biopsy sample. It detects EBV-encoded small RNA inside the tumour cells, sometimes alongside immunostains for viral proteins. This is what confirms a genuine EBV association, as opposed to simply having been exposed to the virus in the past.
In specific high-risk situations — such as after an organ transplant — measuring EBV DNA levels in the blood can help monitor for and track immunosuppression-related lymphoproliferative disease. This is a monitoring tool for particular patients, not a general screening test for the public.
EBV status is only ever one input. The subtype, the stage, and molecular markers such as CD20, CD30 and cell-of-origin are read together. At CION, every lymphoma is discussed by a multidisciplinary tumour board before a diagnosis and plan are finalised, in line with NCCN and ESMO practice. You can see how this fits the full pathway on our Lymphoma Treatment in Hyderabad page.
Reassuringly, treatment for an EBV-associated lymphoma is guided far more by its subtype and stage than by EBV status itself — and many EBV-linked lymphomas, such as Hodgkin lymphoma and Burkitt lymphoma, are among the most treatable. The main building blocks delivered directly by CION are:
Most lymphomas are treated with systemic therapy — combination chemotherapy, often paired with an anti-CD20 monoclonal antibody when the lymphoma carries the CD20 marker. CION's medical oncology and haematology team delivers this directly. Specific drug regimens are individualised and best discussed on the Lymphoma Treatment page rather than self-selected online.
For localised disease or as part of combined treatment, precision radiation therapy (IMRT) is delivered in-house, shaping the beam to the affected area while sparing healthy tissue.
For immunosuppression-related disease such as PTLD, treatment may begin by carefully reducing immunosuppression where possible, alongside antibody or chemotherapy approaches. Advanced cellular therapies and stem-cell transplant, when needed, are coordinated through accredited partner facilities rather than delivered in-house — CION manages the referral and the surrounding care.
The outlook depends on subtype, stage and treatment response — not EBV status alone. To give honest, published context: classic Hodgkin lymphoma has around 80–90% survival and diffuse large B-cell lymphoma around 60–70% in published series (per NCCN and ESMO guidance). These are broad figures that vary considerably by individual, stage and subtype, and are not CION-specific statistics. Your own outlook can only be discussed after your full case is reviewed.
The reason EBV matters more in some people than others often comes down to immune control. A healthy immune system keeps EBV silent for life. When immunity is reduced — for example after an organ transplant or with untreated HIV — the virus can drive lymphoproliferative disease. This is exactly why EBV DNA blood levels are monitored in transplant patients, and why supporting immune health matters. (Source: consistent with NCCN and ESMO lymphoma guidance on immunosuppression-related lymphoproliferative disorders.)
Being an EBV carrier or having had glandular fever is not, on its own, a reason for medical action. But do get assessed promptly if you notice:
And a second opinion is especially worthwhile if you have a confirmed lymphoma and EBV testing on the tissue has not been arranged, if the subtype is uncertain, or before you commit to a treatment path. CION offers a dedicated, free written second-opinion service — a plan built around healing, not billing, with transparent costs explained up front. You can also review the team on our Best Lymphoma Doctors in Hyderabad and Best Lymphoma Hospital in Hyderabad pages. Request your free second opinion or call 18002028726.
Get a free written second opinion from CION's lymphoma tumour board — especially valuable if you have an EBV-positive result or a swollen node that has not yet been fully assessed.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.No. The Epstein-Barr virus is one of the most common human viruses — by adulthood, the large majority of people worldwide carry it, usually after a silent childhood infection or an episode of glandular fever. The overwhelming majority of EBV carriers never develop lymphoma. EBV is one contributing risk factor that, in a small minority and usually alongside other influences such as reduced immunity, can play a part in some lymphoma subtypes. Carrying the virus is not a diagnosis and is not a reason to panic. If you are worried, our lymphoma hub explains the wider picture, and you can always book a free consultation to talk it through.
Glandular fever (infectious mononucleosis) is the illness caused by a first, symptomatic EBV infection, usually in teenagers and young adults. Large population studies have found a modestly raised relative risk of Hodgkin lymphoma in people who had symptomatic glandular fever, particularly in the years afterwards. It is important to keep this in perspective: the absolute risk to any one person remains very low, because Hodgkin lymphoma is uncommon and most people who have had glandular fever never develop it. Having had glandular fever is not something that needs routine cancer screening — but any persistent, unexplained lump or symptom should always be checked.
EBV is detectable in the tumour cells of a proportion of several lymphoma subtypes rather than being tied to one. These include a share of classic Hodgkin lymphoma cases, endemic Burkitt lymphoma (strongly EBV-associated in equatorial regions), extranodal NK/T-cell lymphoma, some diffuse large B-cell lymphomas (including an EBV-positive subtype), and lymphomas that arise when the immune system is suppressed — such as post-transplant lymphoproliferative disorder (PTLD) and HIV-associated lymphomas. Whether a tumour is EBV-positive is confirmed by a laboratory test on the biopsy tissue and can influence how the case is understood.
The definitive test is done on the biopsy tissue, not on a blood antibody test. A pathologist looks for the virus inside the tumour cells using a technique called EBER in-situ hybridisation, which detects small EBV-encoded RNA, sometimes alongside stains for viral proteins. A blood test can also measure EBV DNA levels, which is useful for monitoring certain high-risk situations such as after a transplant. At CION, this specialist tissue testing is arranged as part of the diagnostic work-up, and every result is discussed at our multidisciplinary tumour board. You can read more about the diagnostic pathway on our Lymphoma Treatment in Hyderabad page.
EBV itself is a virus, so it is not inherited the way a gene is. It spreads mainly through saliva — which is why glandular fever is nicknamed the "kissing disease." The lymphomas that EBV is associated with are also, in the vast majority of cases, not inherited. Rarely, an inherited weakness in the immune system can make someone less able to control EBV and raise their risk. For most families, though, an EBV-linked lymphoma is not a hereditary condition. If you are concerned about family history, our page on whether lymphoma is hereditary explains what is and is not passed down.
There is currently no licensed vaccine against EBV and no proven way to eliminate the virus once you carry it, so you cannot directly "prevent" EBV-related lymphoma. What you can do is protect your general immune health, attend recommended care if you are immunosuppressed (for example after an organ transplant or with HIV), and act promptly on persistent symptoms. Our page on whether lymphoma can be prevented sets out the evidence-based steps. Most importantly, EBV-associated lymphomas are treatable, and many are highly treatable when found early.
Not necessarily. The outlook for a lymphoma depends far more on its subtype, stage and how it responds to treatment than on EBV status alone. For some subtypes EBV positivity carries little prognostic weight; for others it can be relevant to how the disease is expected to behave. Published series report that classic Hodgkin lymphoma has around 80–90% and diffuse large B-cell lymphoma around 60–70% survival, though figures vary considerably by individual, stage and subtype (per NCCN and ESMO guidance). Because EBV status is only one piece of the picture, the whole case — including your scans and pathology — is reviewed together by our tumour board before an outlook and plan are discussed.
Browse our complete guide to lymphoma — symptoms, diagnosis, Hodgkin and non-Hodgkin subtypes, treatment, genetics, prognosis, survivorship and cost. Tap any topic to read more.